Search research articles
Contact Us
Filters
Showing results (31-40 of 175) with videos related to
Page
of 18
Sort By:
Sports Medicine (Auckland, N.Z.)
|
December 16, 2014
Neutrophil extracellular traps: a walk on the wild side of exercise immunology
Thomas Beiter, Annunziata Fragasso, Dominik Hartl, et al.
American Journal of Respiratory Cell and Molecular Biology
|
May 6, 2016
Immune Mechanisms in Pulmonary Fibrosis
Saeed Kolahian, Isis E Fernandez, Oliver Eickelberg, et al.
Drug Discovery Today
|
June 1, 2022
Open innovation: A paradigm shift in pharma R&D?
Alexander Schuhmacher, Oliver Gassmann, Doria Bieniok, et al.
Drug Discovery Today
|
July 6, 2021
Systematic risk identification and assessment using a new risk map in pharmaceutical R&D
Alexander Schuhmacher, Clara Brieke, Oliver Gassmann, et al.
Drug Discovery Today
|
April 19, 2026
New perspectives for better R&D performance: lessons learned from leading pharma companies
Alexander Schuhmacher, Oliver Gassmann, Sara Knapp, et al.
Clinical & Developmental Immunology
|
August 3, 2011
Current concepts of hyperinflammation in chronic granulomatous disease
Nikolaus Rieber, Andreas Hector, Taco Kuijpers, et al.
Drug Discovery Today
|
February 3, 2025
A case study assessing the impact of M&A and licensing on FDA drug approvals of leading pharmaceutical companies
Alexander Schuhmacher, Kyrylo Grinchenko, Oliver Gassmann, et al.
Drug Discovery Today
|
March 13, 2025
Corrigendum to "Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006-2022)" [Drug Discov. Today 30(2) (2025) 104291]
Alexander Schuhmacher, Markus Hinder, Elazar Brief, et al.
Drug Discovery Today
|
September 29, 2023
Is the blockbuster imperative broken?
Alexander Schuhmacher, Markus Hinder, Nikolaj Boger, et al.
Nature Reviews. Drug Discovery
|
December 12, 2022
The significance of blockbusters in the pharmaceutical industry
Alexander Schuhmacher, Markus Hinder, Nikolaj Boger, et al.
Page
of 18
Search research articles
Search
Showing results (31-40 of 175) with videos related to
Sort By:
Page
of 18
Sports Medicine (Auckland, N.Z.)
|
December 16, 2014
Neutrophil extracellular traps: a walk on the wild side of exercise immunology
Thomas Beiter, Annunziata Fragasso, Dominik Hartl, et al.
American Journal of Respiratory Cell and Molecular Biology
|
May 6, 2016
Immune Mechanisms in Pulmonary Fibrosis
Saeed Kolahian, Isis E Fernandez, Oliver Eickelberg, et al.
Drug Discovery Today
|
June 1, 2022
Open innovation: A paradigm shift in pharma R&D?
Alexander Schuhmacher, Oliver Gassmann, Doria Bieniok, et al.
Drug Discovery Today
|
July 6, 2021
Systematic risk identification and assessment using a new risk map in pharmaceutical R&D
Alexander Schuhmacher, Clara Brieke, Oliver Gassmann, et al.
Drug Discovery Today
|
April 19, 2026
New perspectives for better R&D performance: lessons learned from leading pharma companies
Alexander Schuhmacher, Oliver Gassmann, Sara Knapp, et al.
Clinical & Developmental Immunology
|
August 3, 2011
Current concepts of hyperinflammation in chronic granulomatous disease
Nikolaus Rieber, Andreas Hector, Taco Kuijpers, et al.
Drug Discovery Today
|
February 3, 2025
A case study assessing the impact of M&A and licensing on FDA drug approvals of leading pharmaceutical companies
Alexander Schuhmacher, Kyrylo Grinchenko, Oliver Gassmann, et al.
Drug Discovery Today
|
March 13, 2025
Corrigendum to "Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006-2022)" [Drug Discov. Today 30(2) (2025) 104291]
Alexander Schuhmacher, Markus Hinder, Elazar Brief, et al.
Drug Discovery Today
|
September 29, 2023
Is the blockbuster imperative broken?
Alexander Schuhmacher, Markus Hinder, Nikolaj Boger, et al.
Nature Reviews. Drug Discovery
|
December 12, 2022
The significance of blockbusters in the pharmaceutical industry
Alexander Schuhmacher, Markus Hinder, Nikolaj Boger, et al.
Page
of 18